Intrexon, Amneal Expand API Platform Pact

Intrexon Corp. and Amneal Pharmaceuticals have formed a second exclusive Channel Collaboration for a target API using Intrexon’s microbial-based expression system with the goal of developing a consistent, scalable, and cost-effective process for the targeted complex API.
 
This is Amneal and Intrexon’s third partnered program this year involving the microbial technology platform to produce APIs more efficiently. By utilizing pathway development as well as strain and fermentation optimization to advance API production processes, Intrexon’s approach aims to replace complex, multistep chemical synthesis of APIs and also avoid resource-intensive isolation of therapeutics from animals and plants.
 
The companies will share R&D costs associated with leveraging their combined capabilities, as well as operating profits.
 
“The power of Intrexon’s synthetic biology platform in conjunction with our generic pharmaceutical development capabilities is well-suited for the advance of novel approaches to active pharmaceutical ingredients, enabling us to think beyond current production platforms,” said Chintu Patel, chief executive officer and Co-Chairman of Amneal. “The progress achieved under our initial ECC led to this expansion of our combined efforts.”
 
“This expanded partnership leverages the strengths of both organizations to develop and commercialize a high quality product for patients through a more modernized and controlled manufacturing process,” said Gregory Frost, Ph.D., senior vice president and head of Intrexon’s Health Sector. “We are pleased to collaborate with Amneal on this API in a profit sharing structure given the value of this potential opportunity.”